Controlled and Targeted Drug Delivery by a UV-responsive Liposome for Overcoming Chemo-resistance in Non-Hodgkin Lymphoma

Chemical Biology and Drug Design

Volumn 86, Issue 4, 2015, Pages 783-794

  Li, Huafei ^a   Guo, Kun ^b   Wu, Cong ^c   Shu, Ling ^b   Guo, Shiwei ^a   Hou, Jing ^c   Zhao, Naping ^c   Wei, Lixin ^a   Man, Xiaobo ^a   Zhang, Li ^c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Yancheng City No1 People's Hospital   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD20; chemotherapy; liposome; multidrug resistance; non Hodgkin lymphoma; serum stability

Indexed keywords

1,2 BIS (10,12 TRICOSADIYNOYL) SN GLYCERO 3 PHOSPHOCHOLINE; DOXORUBICIN; IMMUNOLIPOSOME; PHOSPHATIDYLCHOLINE; RITUXIMAB; UNCLASSIFIED DRUG; 1,2-BIS(10,12-TRICOSADIYNOYL)PHOSPHATIDYLCHOLINE; ALKYNE DERIVATIVE; ANTINEOPLASTIC ANTIBIOTIC; CD20 ANTIGEN; DELAYED RELEASE FORMULATION; IMMOBILIZED ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; LIPOSOME; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BURKITT LYMPHOMA; CANCER INHIBITION; CELL VIABILITY; CIRCULATION TIME; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC50; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; TUMOR VOLUME; ULTRAVIOLET RADIATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; IMMUNOLOGY; LYMPHOMA, NON-HODGKIN; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, IMMOBILIZED; ANTIGENS, CD20; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DIYNES; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIPOSOMES; LYMPHOMA, NON-HODGKIN; MICE, SCID; PHOSPHATIDYLCHOLINES; POLYETHYLENE GLYCOLS; RITUXIMAB; ULTRAVIOLET RAYS;

EID: 84942550874     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12551     Document Type: Article

References (51)

1. Hennessy B.T., Hanrahan E.O., Daly P.A., (2004) Non-Hodgkin lymphoma: an update. Lancet Oncol; 5: 341-353.
2. Shankland K.R., Armitage J.O., Hancock B.W., (2012) Non-Hodgkin lymphoma. Lancet; 380: 848-857.
3. Vose J.M., (2013) Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Am J Hematol; 88: 1082-1088.
4. Chao M.P., Alizadeh A.A., Tang C., Myklebust J.H., Varghese B., Gill S., Jan M., et al., (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell; 142: 699-713.
5. Kim S.J., Kang H.J., Kim J.S., Oh S.Y., Choi C.W., Lee S.I., Won J.H., et al., (2011) Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood; 117: 1958-1965.
6. Reimer P., Chawla S., (2013) Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. J Hematol Oncol; 6: 69.
7. Ganta S., Devalapally H., Shahiwala A., Amiji M., (2008) A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release; 126: 187-204.
8. Dickerson E.B., Blackburn W.H., Smith M.H., Kapa L.B., Lyon L.A., McDonald J.F., (2010) Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer; 10: 10.
9. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y., (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev; 65: 1866-1879.
10. Xue X., Liang X.J., (2012) Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer; 31: 100-109.
11. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G., (2011) Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat; 14: 150-163.
12. See Y.P., Carlsen S.A., Till J.E., Ling V., (1974) Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim Biophys Acta; 373: 242-252.
13. Juliano R.L., Ling V., (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta; 455: 152-162.
14. Chen Y.N., Mickley L.A., Schwartz A.M., Acton E.M., Hwang J.L., Fojo A.T., (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem; 265: 10073-10080.
15. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G., (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science; 258: 1650-1654.
16. Kunjachan S., Rychlik B., Storm G., Kiessling F., Lammers T., (2013) Multidrug resistance: physiological principles and nanomedical solutions. Adv Drug Deliv Rev; 65: 1852-1865.
17. Peetla C., Vijayaraghavalu S., Labhasetwar V., (2013) Biophysics of cell membrane lipids in cancer drug resistance: implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev; 65: 1686-1698.
18. Pop I., Pop L., Vitetta E.S., Ghetie M.A., (2008) Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein. Oncol Rep; 19: 889-895.
19. Ravna A.W., Sager G., (2009) Molecular modeling studies of ABC transporters involved in multidrug resistance. Mini Rev Med Chem; 9: 186-193.
20. Hyde S.C., Emsley P., Hartshorn M.J., Mimmack M.M., Gileadi U., Pearce S.R., Gallagher M.P., Gill D.R., Hubbard R.E., Higgins C.F., (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature; 346: 362-365.
21. Maeda H., Matsumura Y., (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst; 6: 193-210.
22. Maeda H., (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release; 164: 138-144.
23. Matsumura Y., Maeda H., (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res; 46: 6387-6392.
24. Ambudkar S.V., Kim I.W., Sauna Z.E., (2006) The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci; 27: 392-400.
25. Gupta P., Goldenberg D.M., Rossi E.A., Cardillo T.M., Byrd J.C., Muthusamy N., Furman R.R., Chang C.H., (2012) Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood; 119: 3767-3778.
26. Press O.W., Farr A.G., Borroz K.I., Anderson S.K., Martin P.J., (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res; 49: 4906-4912.
27. Press O.W., Howell-Clark J., Anderson S., Bernstein I., (1994) Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood; 83: 1390-1397.
28. Jilani I., O'Brien S., Manshuri T., Thomas D.A., Thomazy V.A., Imam M., Naeem S., Verstovsek S., Kantarjian H., Giles F., Keating M., Albitar M., (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood; 102: 3514-3520.
29. Michel R.B., Mattes M.J., (2002) Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res; 8: 2701-2713.
30. Beers S.A., French R.R., Chan H.T., Lim S.H., Jarrett T.C., Vidal R.M., Wijayaweera S.S., et al., (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood; 115: 5191-5201.
31. Taylor R.P., Lindorfer M.A., (2010) Antigenic modulation and rituximab resistance. Semin Hematol; 47: 124-132.
32. Temprana C.F., Duarte E.L., Taira M.C., Lamy M.T., Del Valle Alonso S., (2010) Structural characterization of photopolymerizable binary liposomes containing diacetylenic and saturated phospholipids. Langmuir; 26: 10084-10092.
33. Wagner N., Dose K., Koch H., Ringsdorf H., (1981) Incorporation of ATP synthetase into long-term stable liposomes of a polymerizable synthetic sulfolipid. FEBS Lett; 132: 313-318.
34. Mussi S.V., Sawant R., Perche F., Oliveira M.C., Azevedo R.B., Ferreira L.A., Torchilin V.P., (2014) Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr Cells. Pharm Res; 31: 1882-1892.
35. Bangham A.D., Standish M.M., Watkins J.C., (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol; 13: 238-252.
36. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., Zalipsky S., (1995) A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta; 1237: 99-108.
37. Huwyler J., Wu D., Pardridge W.M., (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A; 93: 14164-14169.
38. Wu C., Li H., Zhao H., Zhang W., Chen Y., Yue Z., Lu Q., Wan Y., Tian X., Deng A., (2014) Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery. Nanoscale Res Lett; 9: 447.
39. Luo X., Guan R., Chen X., Tao M., Ma J., Zhao J., (2014) Optimization on condition of epigallocatechin-3-gallate (EGCG) nanoliposomes by response surface methodology and cellular uptake studies in Caco-2 cells. Nanoscale Res Lett; 9: 291.
40. Dell'Olio M., Scalzulli R.P., Sanpaolo G., Nobile M., Mantuano F.S., La Sala A., D'Arena G., Miraglia E., Lucania A., Mastrullo L., Nicola C., (2011) Non-pegylated liposomal doxorubicin (Myocet(R)) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma; 52: 1222-1229.
41. Zhang Y., Huo M., Zhou J., Xie S., (2010) pksolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed; 99: 306-314.
42. Li W., Zhao H., Qian W., Li H., Zhang L., Ye Z., Zhang G., Xia M., Li J., Gao J., Li B., Kou G., Dai J., Wang H., Guo Y., (2012) Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials; 33: 5349-5362.
43. Abd ElHafeez S., Torino C., D'Arrigo G., D'Arrigo G., Bolignano D., Provenzano F., Mattace-Raso F., Zoccali C., Tripepi G., (2012) An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method. Aging Clin Exp Res; 24: 203-206.
44. Jager K.J., van Dijk P.C., Zoccali C., Dekker F.W., (2008) The analysis of survival data: the Kaplan-Meier method. Kidney Int; 74: 560-565.
45. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H., (2013) The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells. Biomaterials; 34: 5617-5627.
46. Flaten G.E., Chang T.T., Phillips W.T., Brandl M., Bao A., Goins B., (2013) Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution. J Liposome Res; 23: 70-81.
47. Slingerland M., Guchelaar H.J., Gelderblom H., (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today; 17: 160-166.
48. Wu Y., Yang Y., Zhang F.C., Wu C., Lu W.L., Mei X.G., (2011) Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. J Liposome Res; 21: 221-228.
49. Chang A., (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer; 71: 3-10.
50. Li W., Li H., Li J., Wang H., Zhao H., Zhang L., Xia Y., Ye Z., Gao J., Dai J., Wang H., Guo Y., (2012) Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. Int J Nanomedicine; 7: 4661-4677.
51. Wang M., Thanou M., (2010) Targeting nanoparticles to cancer. Pharmacol Res; 62: 90-99.